COVID ‐19: a pandemic experience that illuminates potential reforms to health researchCommentary Published on 2020-10-192022-11-01 Journal: EMBO Molecular Medicine [Category] COVID-19, MERS, SARS, [키워드] Biomedical research clinical trial COVID COVID‐19 globe Health help IMPROVE Microbiology, Virology & Host Pathogen Interaction mounted overcome pandemic provide Research researcher resource S&S: Ethics Science therapeutic option [DOI] 10.15252/emmm.202013278 PMC 바로가기 [Article Type] Commentary
Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent IndividualsObservation Published on 2020-10-162022-10-29 Journal: mBio [Category] COVID-19, MERS, SARS, [키워드] absence acute COVID-19 acute respiratory syndrome Analysis approach Clinical efficacy clinical trial collected convalescent convalescent individual convalescent plasma convalescent plasma trial coronavirus coronavirus disease COVID-19 COVID-19 patient cross-reactivity D614G variant Decline Donor effective vaccine Efficacy ELISA evaluate for inclusion globe glycoprotein Humoral response IgA IgG IgM individual Infection interval neutralization neutralization activity neutralize Neutralizing activity neutralizing antibody Neutralizing titer onset of symptom patients performed plasma plasma neutralization activity positive Prevent PROTECT pseudoparticle RBD repeated required resolution of symptoms response Safe SARS-CoV-2 SARS-COV-2 infection significant decrease spike spike glycoproteins Symptoms therapeutic options therapy thought transfer transfusion treat Treatment Vaccine while wild-type SARS-CoV-2 [DOI] 10.1128/mBio.02590-20 PMC 바로가기 [Article Type] Observation
A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the P yridostigmine I n S evere CO vid-19 (PISCO) trial protocolStudy Protocol Published on 2020-10-162022-10-28 Journal: BMC Infectious Diseases [Category] COVID-19, MERS, SARS, [키워드] ACh acute inflammatory response acute respiratory distress acute respiratory syndrome ARDS chronic inflammatory diseases clinical evidence clinical trial coronavirus coronavirus disease COVID-19 death decrease double-blinded Efficacy electrical Evidence hospitalized patient immunomodulation improve clinical outcome increase Infection Inflammation Inflammatory Inflammatory reflex inhibitor Invasive mechanical ventilation low dose mechanism mimicking modulate Mortality multicenter parallel-group Patient phase 2/3 placebo-controlled placebo-controlled trial pulmonary damage pyridostigmine Randomized recent reduce reduce mortality Registered Respiratory failure SARS-CoV-2 severe COVID-19 severe SARS-CoV-2 syndrome systemic inflammation systemic inflammatory response trial protocol turn [DOI] 10.1186/s12879-020-05485-7 PMC 바로가기 [Article Type] Study Protocol
Viral Related Tools against SARS-CoV-2Review Published on 2020-10-162022-10-28 Journal: Viruses [Category] COVID-19, MERS, SARS, [키워드] antibody bacteriophage clinical trial coronavirus SARS-CoV-2 COVID-19 CRISPR CRISPR-Ca diagnose Diagnosis diagnostic disease Health knowledge phages prevention produced Research resource SARS-CoV-2 Scientific community Spread the patient therapy Treatment Vaccine virus viruses [DOI] 10.3390/v12101172 PMC 바로가기 [Article Type] Review
The upshot of Polyphenolic compounds on immunity amid COVID-19 pandemic and other emerging communicable diseases: An appraisalReview Published on 2020-10-152022-10-30 Journal: Natural Products and Bioprospecting [Category] COVID-19, [키워드] Antiviral benefit Cancer chronic disease clinical trial communicable Compound compounds COVID-19 COVID-19 pandemic COVID‐19 diabetes Diseases drug ENhance Health Host immune response human pathogen Immunity increasingly infections Infectious diseases mechanisms MERS natural product Neurological diseases pharmacological physiological polyphenol polyphenols respiratory problem respiratory tract SARS viral infection viral infectious diseases [DOI] 10.1007/s13659-020-00271-z PMC 바로가기 [Article Type] Review
Sepsis, Phages, and COVID-19Review Published on 2020-10-152022-10-28 Journal: Pathogens [Category] COVID-19, [키워드] Anti-viral Bacteremia Bacterial infection clinical trial COVID-19 example excessive inflammatory response help Immunity Local occur Patient phage Sepsis severe COVID-19 syndrome therapy Treatment [DOI] 10.3390/pathogens9100844 PMC 바로가기 [Article Type] Review
Natural Plant Products: A Less Focused Aspect for the COVID-19 Viral OutbreakPlant Science Published on 2020-10-152022-10-31 Journal: Frontiers in Plant Science [Category] COVID-19, [키워드] antibodies aspect caused Clinical data clinical trial clinical trials conducted contribute contributed coronavirus coronavirus disease of 2019 COVID-19 described develop disadvantage drug Final human disease identify measure medications molecular docking natural natural compounds nCoV Novel coronavirus other disease Outbreaks pandemic Perspective Phytoconstituents plant positive random Replication required Research Scientific community severe acute respiratory syndrome coronavirus 2 tap therapeutic Treatment Trial Vaccine viruses [DOI] 10.3389/fpls.2020.568890 PMC 바로가기 [Article Type] Plant Science
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)Research article Published on 2020-10-152022-10-05 Journal: EClinicalMedicine [Category] 치료제, [키워드] Acute respiratory insufficiency Admission affected age Antiviral antivirals baseline Basic science boost C-reactive protein carried Characteristics clinical Clinical outcome clinical outcomes clinical trial Cohort collected Comorbidities Comorbidity COVID-19 COVID-19 outbreak COVID-19 research cyclosporine A demographic diabete Diabetes Mellitus Diagnosis died disease Diseases epidemiological Factor finding funding Glucocorticoids health system Hospitalized Hydroxychloroquine Hyperinflammation state hyperinflammatory phase hypertension immunosuppressants implication in-hospital mortality Inflammatory laboratory data male Mortality multivariate logistic regression multivariate model nasal swab Non-survivors observation Odds ratio Older age outcome paO2/fiO2 pathway Patient Positive test potential risk receiving reduce retrospective risk of death RT-PCR assay SARS-COV-2 infection severe COVID-19 severe COVID-19 patients significant decrease single-center Spanish subject survivor therapy Tocilizumab tocilizumab therapy Treatment [DOI] 10.1016/j.eclinm.2020.100591 [Article Type] Research article
Efficacy and safety of tocilizumab in COVID-19 patientsResearch Paper Published on 2020-10-152022-10-28 Journal: Aging (Albany NY) [Category] COVID-19, [키워드] A significant reduction addition Adverse drug reactions analyzed C-reactive protein changes in clinical manifestations Clinical outcome clinical trial cough COVID-19 COVID-19 patient Critical CT scan Cytokine storm effective Efficacy and safety enrolled Fever Huoshenshan Hospital IL-6 IMPROVE in some interleukin-6 Laboratory test Patient reported Retrospective study SARS-CoV-2 severe coronavirus disease severe COVID-19 Shortness of breath therapeutic strategy Tocilizumab tocilizumab administration treated Treatment Wuhan, China [DOI] 10.18632/aging.103988 PMC 바로가기 [Article Type] Research Paper
Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patientsReview Published on 2020-10-152022-10-29 Journal: Stem Cell Research & Therapy [Category] COVID-19, MERS, SARS, [키워드] acute lung injury alveolar fluid clearance applicability approved ARDS characterized clinical study clinical trial clinical trials Consensus correlation COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients effective effective therapy Efficacy endothelial ENhance epithelial Exosome global public health highlight impacted Infection International less lung mechanism of action mesenchymal stem cell MSC MSC therapy MSCs Pneumonia Potential promote reduce Registered risk Safe SARS-CoV-2 stem cell stem cells the cytokine storm the SARS-CoV-2 therapeutic therapeutic effect therapeutic option therapy Thromboembolism treat treating COVID-19 patients Treatment unique [DOI] 10.1186/s13287-020-01963-6 PMC 바로가기 [Article Type] Review